XML 22 R13.htm IDEA: XBRL DOCUMENT v3.25.2
Stock Options
9 Months Ended
Jul. 31, 2025
Stock Options [Abstract]  
Stock Options
8. Stock Options

 

  a. On January 6, 2025, the shareholders of the Company approved the Omnibus Equity Incentive Plan, the “Omnibus Plan”. Pursuant to the Omnibus Plan, the Company is authorized to grant options or RSUs to officers, directors, employees and consultants enabling them to acquire, together with” Options”, “Awards” or “Stock Options” as defined, up to 20% of the Company’s issued and outstanding Common Shares (after taking into account existing awards from the Company’s 2021 stock option plan). The Awards can be granted for a maximum of 10 years and vest as determined by the Board.

 

The maximum number of common shares reserved for issuance in any 12-month period to a related party consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant (and may not exceed 15% in total, to all related parties). The maximum number of common shares reserved for issuance in any 12-month period to any investor relations service provider may not exceed 2% of the issued and outstanding common shares at the date of the grant.

 

  b. The following table summarizes the changes in the Company’s stock options for the periods ended July 31, 2025 and October 31, 2024:

 

    Number
of options
    Weighted average
exercise price (C$)
    Weighted average
exercise price
(USD$)
 
Outstanding, October 31, 2023     5,588     C$ 603.12     $ 434.82  
                         
Expired     (67 )     720.00       533.14  
                         
Outstanding, October 31, 2024     5,521     C$ 601.71     $ 432.38  
     
 
     
 
     
 
 
Outstanding, July 31, 2025     5,521     C$ 601.70     $ 434.63  
                         
Exercisable, July 31, 2025     5,509     C$ 602.94     $ 435.53  
  c. Additional information regarding stock options outstanding as of July 31, 2025, is as follows:

 

Outstanding           Exercisable        
Number of
stock options
    Weighted
average
remaining
contractual life
(years)
    Weighted
average
exercise price
(C$)
    Weighted
average
exercise price
(USD$)
    Number of
stock
options
    Weighted
average
exercise price
(C$)
    Weighted
average
exercise price
(USD$)
 
  533        0.82     C$ 166.50     $  120.27        533     C$ 166.50     $  120.27  
  978        6.51       504.00        364.06        978       504.00        364.06  
  1,166        0.82       675.00        487.58        1,166       675.00        487.58  
  200        3.75       702.00        507.08        200       702.00        507.08  
  133        1.14       747.00        539.58        133       747.00        539.58  
  422        6.36       612.00        442.07        422       612.00        442.07  
  1,044        6.51       720.00        520.08        1,044       720.00        520.08  
  667        0.92       756.00        546.08        667       756.00        546.08  
  111        6.36       900.00        650.10        111       900.00        650.10  
  61        7.82       315.00        227.54        61       315.00        227.54  
  156        7.91       504.00        364.06        156       504.00        364.06  
  50        7.94       32.39        23.40        38       32.39        23.40  
  5,521        3.91     C$ 601.70     $  434.63        5,509     C$ 602.94     $  435.53  

  

The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions:

 

    Nine months
ended
July 31,
2025
    Nine months
ended
July 31,
2024
 
Risk-free interest rate     4.46 %     4.05 %
Expected life (in years)     3.86       4.86  
Expected volatility      112.20%-134.44 %     121.10%-133.14 %

 

Expected volatility was determined by calculating the historical volatility of the comparison companies’ share price over the previous 8.4 years. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of no transferability, exercise restrictions, and behavioral considerations.

 

  d. The portion of the total fair value of stock options expensed during the three and nine months ended July 31, 2025, was $Nil and $3,264, respectively (2024 - $14,879 and $71,793, respectively) which was recorded in share-based compensation expense.